1. Home
  2. HUMA
  3. HUMA News

Latest Humacyte Inc. (HUMA) News on November 27, 2025

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
HUMA

GlobeNewswire

7 days ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
HUMA

GlobeNewswire

14 days ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Why Humacyte (HUMA) Is Rising After Positive Phase 3 Results in High-Risk Hemodialysis Patients
HUMA

Simply Wall St.

14 days ago

Why Humacyte (HUMA) Is Rising After Positive Phase 3 Results in High-Risk Hemodialysis Patients

HUMA

GuruFocus.com

14 days ago

Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ...

Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
HUMA

Zacks

15 days ago

Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
HUMA

GlobeNewswire

15 days ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Earnings To Watch: Humacyte Inc (HUMA) Reports Q3 2025 Result
HUMA

GuruFocus.com

16 days ago

Earnings To Watch: Humacyte Inc (HUMA) Reports Q3 2025 Result

Humacyte (HUMA): Evaluating Valuation Following Promising Phase 3 V007 Results in Hemodialysis Access
HUMA

Simply Wall St.

16 days ago

Humacyte (HUMA): Evaluating Valuation Following Promising Phase 3 V007 Results in Hemodialysis Access

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
HUMA

GlobeNewswire

17 days ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
HUMA

Zacks

20 days ago

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
HUMA

GlobeNewswire

21 days ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
HUMA

Zacks

a month ago

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
HUMA

GlobeNewswire

a month ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
HUMA

Zacks

a month ago

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

Humacyte (HUMA): Valuation in Focus After Promising Ukraine Trauma Results
HUMA

Simply Wall St.

a month ago

Humacyte (HUMA): Valuation in Focus After Promising Ukraine Trauma Results

Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors
HUMA

Zacks

a month ago

Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors

HUMA

ACCESS Newswire

a month ago

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise
HUMA

Simply Wall St.

a month ago

Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
HUMA

Zacks

2 months ago

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

HUMA

MT Newswires

2 months ago

Top Midday Decliners

Humacyte Gains 43%, Insider Trades Reap Benefit
HUMA

Simply Wall St.

2 months ago

Humacyte Gains 43%, Insider Trades Reap Benefit

HUMA

MT Newswires

2 months ago

Humacyte Prices $60 Million Oversubscribed Registered Direct Offering; Shares Tumble

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
HUMA

GlobeNewswire

2 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

HUMA

MT Newswires

2 months ago

Humacyte Says Symvess Real-World Data Show 87% Patency Rate, Zero Infections

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
HUMA

GlobeNewswire

2 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know
HUMA

Zacks

5 months ago

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know

Owning 40% shares,institutional owners seem interested in Humacyte, Inc. (NASDAQ:HUMA),
HUMA

Simply Wall St.

5 months ago

Owning 40% shares,institutional owners seem interested in Humacyte, Inc. (NASDAQ:HUMA),

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know
HUMA

Zacks

5 months ago

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
HUMA

GlobeNewswire

6 months ago

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
HUMA

GlobeNewswire

6 months ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Exploring 3 High Growth Tech Stocks In The US Market
HUMA

Simply Wall St.

6 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
HUMA

GlobeNewswire

6 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
HUMA

GlobeNewswire

6 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
HUMA

GlobeNewswire

7 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte Insiders Placed Bullish Bets Worth US$949.4k
HUMA

Simply Wall St.

7 months ago

Humacyte Insiders Placed Bullish Bets Worth US$949.4k

Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz
HUMA

TipRanks

8 months ago

Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz

Humacyte price target lowered to $8 from $10 at BTIG
HUMA

TipRanks

8 months ago

Humacyte price target lowered to $8 from $10 at BTIG

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
HUMA

GlobeNewswire

8 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
HUMA

GlobeNewswire

8 months ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
HUMA

GlobeNewswire

8 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock
HUMA

GlobeNewswire

8 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
HUMA

GlobeNewswire

9 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Trestle Bio Announces Research Collaboration with Humacyte
HUMA

Business Wire

9 months ago

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
HUMA

GlobeNewswire

9 months ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
HUMA

GlobeNewswire

9 months ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
HUMA

GlobeNewswire

9 months ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
HUMA

GlobeNewswire

9 months ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?
HUMA

Simply Wall St.

9 months ago

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
HUMA

GlobeNewswire

10 months ago

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
HUMA

GlobeNewswire

10 months ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
HUMA

GlobeNewswire

10 months ago

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Humacyte price target raised to $17 from $15 at Benchmark
HUMA

TipRanks

a year ago

Humacyte price target raised to $17 from $15 at Benchmark

High Growth Tech Stocks to Watch in December 2024
HUMA

Simply Wall St.

a year ago

High Growth Tech Stocks to Watch in December 2024

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
HUMA

GlobeNewswire

a year ago

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m
HUMA

Simply Wall St.

a year ago

Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
HUMA

GlobeNewswire

a year ago

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
HUMA

GlobeNewswire

a year ago

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

Insider Buyers At Humacyte Likely Disappointed With 17% Slide
HUMA

Simply Wall St.

a year ago

Insider Buyers At Humacyte Likely Disappointed With 17% Slide

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
HUMA

GlobeNewswire

a year ago

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
HUMA

GlobeNewswire

a year ago

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
HUMA

GlobeNewswire

a year ago

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

Humacyte Third Quarter 2024 Financial Results and Business Update
HUMA

GlobeNewswire

a year ago

Humacyte Third Quarter 2024 Financial Results and Business Update

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
HUMA

GlobeNewswire

a year ago

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
HUMA

GlobeNewswire

a year ago

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

High Growth Tech Stocks to Watch in October 2024
HUMA

Simply Wall St.

a year ago

High Growth Tech Stocks to Watch in October 2024

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
HUMA

GlobeNewswire

a year ago

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab
HUMA

The Wall Street Journal

a year ago

‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
HUMA

GlobeNewswire

a year ago

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

Humacyte Launches $30M Stock and Warrants Offering
HUMA

TipRanks

a year ago

Humacyte Launches $30M Stock and Warrants Offering

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
HUMA

GlobeNewswire

a year ago

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
HUMA

GlobeNewswire

a year ago

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

Exploring Three High Growth Tech Stocks in the United States
HUMA

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks in the United States

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)
HUMA

GlobeNewswire

a year ago

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

Humacyte to Participate at Upcoming Investor Conferences in September
HUMA

GlobeNewswire

a year ago

Humacyte to Participate at Upcoming Investor Conferences in September

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
HUMA

GlobeNewswire

a year ago

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

Humacyte Second Quarter 2024 Financial Results and Business Update
HUMA

GlobeNewswire

a year ago

Humacyte Second Quarter 2024 Financial Results and Business Update

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024
HUMA

GlobeNewswire

a year ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
HUMA

GlobeNewswire

a year ago

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

Companies Like Humacyte (NASDAQ:HUMA) Are In A Position To Invest In Growth
HUMA

Simply Wall St.

a year ago

Companies Like Humacyte (NASDAQ:HUMA) Are In A Position To Invest In Growth

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis
HUMA

GlobeNewswire

a year ago

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
HUMA

GlobeNewswire

a year ago

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
HUMA

Business Wire

a year ago

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs

While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership
HUMA

Simply Wall St.

a year ago

While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
HUMA

GlobeNewswire

a year ago

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
HUMA

GlobeNewswire

a year ago

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
HUMA

GlobeNewswire

a year ago

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate
HUMA

Simply Wall St.

a year ago

This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate

Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)
HUMA

GuruFocus.com

a year ago

Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)

Humacyte to Present at the Jefferies Global Healthcare Conference
HUMA

GlobeNewswire

a year ago

Humacyte to Present at the Jefferies Global Healthcare Conference

This Humacyte Insider Increased Their Holding By 91% Last Year
HUMA

Simply Wall St.

2 years ago

This Humacyte Insider Increased Their Holding By 91% Last Year

Humacyte to Participate at Upcoming Investor Conferences in May
HUMA

GlobeNewswire

2 years ago

Humacyte to Participate at Upcoming Investor Conferences in May

HUMA

GuruFocus.com

2 years ago

Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances

Humacyte First Quarter 2024 Financial Results and Business Update
HUMA

GlobeNewswire

2 years ago

Humacyte First Quarter 2024 Financial Results and Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
HUMA

GlobeNewswire

2 years ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
HUMA

GlobeNewswire

2 years ago

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024

Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript
HUMA

Insider Monkey

2 years ago

Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
HUMA

GlobeNewswire

2 years ago

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
HUMA

GlobeNewswire

2 years ago

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
HUMA

GlobeNewswire

2 years ago

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
HUMA

GlobeNewswire

2 years ago

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

Share on Social Networks: